Stability and Administration Timeframe for Reconstituted Etoposide and Cisplatin
Etoposide and cisplatin admixtures should be administered within 8 hours of reconstitution to ensure optimal stability and drug potency.
Evidence-Based Timeframe
The most direct evidence addressing this question comes from a stability study that specifically examined etoposide and cisplatin combinations in intravenous admixtures 1. This research demonstrated that:
- Both drugs maintained >90% of their initial concentration for up to 8 hours when stored together in IV admixtures at room temperature
- After 24 hours, significant degradation occurred, with some admixtures (particularly those containing etoposide 400 mcg/mL with cisplatin 200 mcg/mL in 0.9% sodium chloride) actually precipitating
- The concentration decrease was influenced by the type of IV solution used and the presence of additives
Clinical Practice Implications
While the NCCN guidelines 2, 3 specify the dosing regimens for etoposide (100 mg/m² IV on days 1-5) and cisplatin (20 mg/m² IV on days 1-5) in various cancer treatment protocols including germ cell tumors and ovarian cancer, they do not explicitly state reconstitution timeframes. However, the FDA drug labels provide important pharmacokinetic context:
- Cisplatin has a plasma half-life of 20-30 minutes following bolus administration 4
- Etoposide exhibits a distribution half-life of approximately 1.5 hours 5
Practical Recommendations
For optimal patient safety and drug efficacy:
- Prepare etoposide and cisplatin admixtures as close to administration time as possible
- Do not exceed 8 hours between reconstitution and completion of infusion
- Protect admixtures from light when possible (though this had minimal impact in the stability study)
- Avoid adding multiple additives (mannitol, potassium chloride) to the admixture, as these may accelerate degradation
- Visually inspect solutions before administration for any precipitation or discoloration
Common Pitfalls to Avoid
- Do not prepare these admixtures the night before for next-day administration
- Avoid batch preparation of multiple doses at once
- Be particularly cautious with higher concentrations of etoposide (≥400 mcg/mL), which showed greater instability
- Do not assume that refrigeration extends stability—the study used room temperature storage, which is standard practice
The 8-hour window provides a safe margin while accounting for preparation time, transport to the patient care area, and the actual infusion duration.